| BIOGEN INC ORD SHS | 232.65 |
| Date/Time | 08/21 / 15:42 |
| Chg. / Chg.(%) | - / |
| Bid | - |
| Ask | - |
| Open | 232.65 |
| Previous Close | 231.66 |
| High | 232.65 |
| Low | 232.65 |
| Volume [USD] | 2,093.85 |
| Volume [Units] | 9 |
| Price fixings | 1 |
| ISIN | US09062X1037 |
| Security | 0R1B |
| Exchange | London International |
| Type | Stock |
Other Exchanges
| Exchange | Last | Volume | |
|---|---|---|---|
| NASDAQ | 233.3600 |  |
29,238 |
| Cboe US | 233.06 | |
1,242 |
| IEX | 232.78 | |
924 |
| Frankfurt | 209.4500 | |
10 |
| TradeGate | 209.300 | |
10 |
| München | 209.40 | |
1 |
| Vienna Globa.. | 210.40 | |
0 |
| Hamburg | 209.40 | |
0 |
| Düsseldorf | 209.10 | |
0 |
| Berlin | 210.45 | |
0 |
| Hannover | 209.40 | |
0 |
| Lang & Schwa.. | 210.550 | |
|
| gettex | 210.250 | |
|
| Stuttgart | 209.450 | |
|
| Xetra | 209.95 | 65 | |
| London Inter.. | 232.65 | 9 | |
| SIX Swiss Ex.. | 232.00 | ||
| Mexico | 4,569.20 | 200 |
News
- Biogen and Invitae Announce Availability of Rapid Results in Genetic Testing Program for Spinal Muscular Atrophy (SMA) to Improve Speed of Diagnosis for Patients
08/20/2019 / 13:30 - GlobeNewswire - Diroximel Fumarate Demonstrated Significantly Improved Gastrointestinal Tolerability Profile Compared to Dimethyl Fumarate in Patients with Multiple Sclerosis
07/30/2019 / 13:30 - GlobeNewswire - Turning Point Therapeutics Names Carol Gallagher, Pharm.D. to its Board of Directors
07/25/2019 / 14:30 - GlobeNewswire - Biogen's GAAP diluted EPS in Q2 increases 88% YoY
07/23/2019 / 12:35 - TeleTrader - Biogen Announces New Data Further Establishing SPINRAZA® (nusinersen) as a Foundation of Care in Spinal Muscular Atrophy for a Broad Range of Patients
07/01/2019 / 13:30 - GlobeNewswire
Real-time